Corvus Pharmaceuticals
CRVS
CRVS
52 hedge funds and large institutions have $28M invested in Corvus Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
2.68% less ownership
Funds ownership: 41.86% → 39.18% (-2.7%)
37% less capital invested
Capital invested by funds: $44.6M → $28M (-$16.6M)
Holders
52
Holding in Top 10
1
Calls
$114K
Puts
$113K
Top Buyers
| 1 | +$438K | |
| 2 | +$201K | |
| 3 | +$158K | |
| 4 |
Two Sigma Advisers
New York
|
+$102K |
| 5 |
JPMorgan Chase & Co
New York
|
+$100K |
Top Sellers
| 1 | -$1.15M | |
| 2 | -$458K | |
| 3 | -$223K | |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$147K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$132K |